Neural Regeneration Research ›› 2021, Vol. 16 ›› Issue (9): 1730-1739.doi: 10.4103/1673-5374.306066

Previous Articles     Next Articles

Promising drug targets and associated therapeutic interventions in Parkinson’s disease

Sachchida Nand Rai1, #, Payal Singh2, #, Ritu Varshney3, #, Vivek K. Chaturvedi1, Emanuel Vamanu4, M. P. Singh1, *, Brijesh Kumar Singh5, *   

  1. 1Centre of Biotechnology, University of Allahabad, Prayagraj, India; 2Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India; 3Department of Bioengineering and Chemistry, Indian Institute of Technology Gandhinagar, Palaj, Gujarat, India; 4Faculty of Biotechnology, University of Agronomic Science and Veterinary Medicine, Bucharest, Romania; 5Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
  • Online:2021-09-15 Published:2021-02-05
  • Contact: M. P. Singh, PhD, mpsingh.16@gmail.com; Brijesh Kumar Singh, PhD, bks.cumc@gmail.com.
  • Supported by:
    This work was supported by UGC Dr. D.S. Kothari Postdoctoral scheme by awarding the fellowship to SNR (Ref. No-F.4-2/2006 (BSR)/BL/19-20/0032). 

PDF

108

Abstract: Parkinson’s disease (PD) is one of the most debilitating brain diseases. Despite the availability of symptomatic treatments, response towards the health of PD patients remains scarce. To fulfil the medical needs of the PD patients, an efficacious and etiological treatment is required. In this review, we have compiled the information covering limitations of current therapeutic options in PD, novel drug targets for PD, and finally, the role of some critical beneficial natural products to control the progression of PD.

Key words: dopamine, epigenetics, gene therapies, glutamate receptor, levodopa, molecular chaperones, monoamine oxidase B, mucuna alpha-synuclein, Parkinson’s disease, striatum, substantia nigra